{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T19:59:44Z","timestamp":1768420784288,"version":"3.49.0"},"reference-count":20,"publisher":"Scientific Scholar","content-domain":{"domain":["nmji.in"],"crossmark-restriction":true},"short-container-title":["NMJI"],"abstract":"\n Background<\/jats:title>\n Patients of ovarian cancer who respond to the initial chemotherapy (CT) regimen may respond again to the same drugs after relapse. We aimed to evaluate the survival of patients with recurrent ovarian cancer (ROC) treated with second-line CT drugs such as liposomal doxorubicin, paclitaxel\/carboplatin, and\/or bevacizumab.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Electronic medical records of ovarian cancer patients registered between January 2009 and December 2017 were reviewed to identify those with ROC. Data regarding demographics, clinical characteristics, treatment, recurrence, vital status at last contact, etc. were retrieved. The log-rank test was applied to compare the Kaplan-Meier curves for survival analysis.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 119 cases met the inclusion criteria. The median age at diagnosis and relapse was 49 and 51 years, respectively. The medians for progression-free survival (PFS) and post-relapse survival (PRS) were 19 (95% CI 10.34\u201321.66) months and 34 (95% CI 37.17\u201356.83) months, respectively. The PFS was significantly higher among premenopausal women (p=0.025). Patients treated with paclitaxel\/carboplatin-based second-line CT had significantly higher PRS compared to those treated with liposomal doxorubicin\/carboplatin (p<0.001). Overall survival was also significantly different between the stage groups (p=0.003).<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n The 5-year PFS rate in ROC treated with second-line CT is <20%. The rate of secondary recurrence is moderately high, leading to reduced survival. Paclitaxel\/carboplatin-based second-line CT significantly increases PRS among ROC patients. The probability of mortality increases as the stage advances.<\/jats:p>\n <\/jats:sec>","DOI":"10.25259\/nmji_449_2023","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T11:34:15Z","timestamp":1768390455000},"page":"6-12","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Survival analysis of second-line chemotherapy in platinum-sensitive relapsed ovarian cancer patients"],"prefix":"10.25259","volume":"39","author":[{"given":"VINEET","family":"TALWAR","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, Rohini, Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ATIKA","family":"DOGRA","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, Rohini, Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"VARUN","family":"GOEL","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, Rohini, Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"VIDYA","family":"KRISHNA","sequence":"additional","affiliation":[{"name":"Department of Research, Rajiv Gandhi Cancer Institute and Research Centre, Rohini, Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"10.25259\/NMJI_449_2023\/ref-1","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2147\/IJWH.S197604","article-title":"Ovarian cancer in the world: Epidemiology and risk factors","volume":"11","author":"Momenimovahed","year":"2019","journal-title":"Int J Womens Health"},{"key":"10.25259\/NMJI_449_2023\/ref-2","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/nrc1123","article-title":"Ovarian cancer: Strategies for overcoming resistance to chemotherapy","volume":"3","author":"Agarwal","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"10.25259\/NMJI_449_2023\/ref-3","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.1200\/JCO.2004.05.195","article-title":"Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: Implications for patient management and clinical trial design","volume":"22","author":"Markman","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.25259\/NMJI_449_2023\/ref-4","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.4103\/jcrt.JCRT_949_20","article-title":"First-line chemotherapy analysis on survival in carcinoma ovary patients: Data from a northern Indian cancer center","volume":"18","author":"Dogra","year":"2022","journal-title":"J Cancer Res Ther"},{"key":"10.25259\/NMJI_449_2023\/ref-5","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.25259\/NMJI_449_2023\/ref-6","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1007\/s11095-008-9690-4","article-title":"Cancer is a preventable disease that requires major lifestyle changes","volume":"25","author":"Anand","year":"2008","journal-title":"Pharm Res"},{"key":"10.25259\/NMJI_449_2023\/ref-7","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1111\/j.1471-0528.2008.01772.x","article-title":"Identifying symptoms of ovarian cancer: A qualitative and quantitative study","volume":"115","author":"Bankhead","year":"2008","journal-title":"BJOG"},{"key":"10.25259\/NMJI_449_2023\/ref-8","first-page":"937","article-title":"Diagnosis and management of ovarian cancer","volume":"93","author":"Doubeni","year":"2016","journal-title":"Am Fam Physician"},{"key":"10.25259\/NMJI_449_2023\/ref-9","doi-asserted-by":"publisher","first-page":"952","DOI":"10.3390\/ijms20040952","article-title":"High-grade serous ovarian cancer: Basic sciences, clinical and therapeutic standpoints","volume":"20","author":"Lisio","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.25259\/NMJI_449_2023\/ref-10","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.1002\/cncr.25203","article-title":"CA 125 and the detection of recurrent ovarian cancer: A reasonably accurate biomarker for a difficult disease","volume":"116","author":"Bast","year":"2010","journal-title":"Cancer"},{"key":"10.25259\/NMJI_449_2023\/ref-11","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13048-021-00842-9","article-title":"The survival outcome and complication of secondary cytoreductive surgery plus chemotherapy in recurrent ovarian cancer: A systematic review and meta-analysis","volume":"14","author":"Ding","year":"2021","journal-title":"J Ovarian Res"},{"key":"10.25259\/NMJI_449_2023\/ref-12","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1186\/s12885-020-07658-8","article-title":"Survival impact of extended cycles of second-line chemotherapy in platinum-sensitive relapsed ovarian cancer patients with residual tumor after six cycles","volume":"20","author":"Kim","year":"2020","journal-title":"BMC Cancer"},{"key":"10.25259\/NMJI_449_2023\/ref-13","doi-asserted-by":"publisher","first-page":"353","DOI":"10.4183\/aeb.2018.353","article-title":"Clinical prognostic factors in pre-and post-menopausal women with ovarian carcinoma","volume":"14","author":"Trifanescu","year":"2018","journal-title":"Acta Endocrinol (Buchar)"},{"key":"10.25259\/NMJI_449_2023\/ref-14","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.ejca.2014.11.017","article-title":"Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: Results from a subset analysis of the CALYPSO phase III trial","volume":"51","author":"Mahner","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.25259\/NMJI_449_2023\/ref-15","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"key":"10.25259\/NMJI_449_2023\/ref-16","doi-asserted-by":"publisher","first-page":"872","DOI":"10.7150\/jca.17664","article-title":"Overall survival and post-progression survival are potent endpoints in phase III trials of second\/third-line chemotherapy for advanced or recurrent epithelial ovarian cancer","volume":"9","author":"Shimokawa","year":"2018","journal-title":"J Cancer"},{"key":"10.25259\/NMJI_449_2023\/ref-17","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1902626","article-title":"Secondary surgical cytoreduction for recurrent ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N Engl J Med"},{"key":"10.25259\/NMJI_449_2023\/ref-18","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.ygyno.2022.07.004","article-title":"What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long-term survivors in NRG\/GOG randomized clinical trials","volume":"166","author":"Pitiyarachchi","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.25259\/NMJI_449_2023\/ref-19","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3892\/mco.2017.1266","article-title":"Factors favouring long-term survival following recurrence in ovarian cancer","volume":"7","author":"Soyama","year":"2017","journal-title":"Mol Clin Oncol"},{"key":"10.25259\/NMJI_449_2023\/ref-20","doi-asserted-by":"publisher","first-page":"e10881","DOI":"10.1097\/MD.0000000000010881","article-title":"Clear cell carcinoma of the ovary: Clinicopathologic features and outcomes in a Chinese cohort","volume":"97","author":"Tang","year":"2018","journal-title":"Medicine (Baltimore)"}],"container-title":["The National Medical Journal of India"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/nmji.in\/survival-analysis-of-second-line-chemotherapy-in-platinum-sensitive-relapsed-ovarian-cancer-patients\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nmji.in\/survival-analysis-of-second-line-chemotherapy-in-platinum-sensitive-relapsed-ovarian-cancer-patients\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T11:34:16Z","timestamp":1768390456000},"score":1,"resource":{"primary":{"URL":"https:\/\/nmji.in\/survival-analysis-of-second-line-chemotherapy-in-platinum-sensitive-relapsed-ovarian-cancer-patients\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":20,"alternative-id":["10.25259\/NMJI_449_2023"],"URL":"https:\/\/doi.org\/10.25259\/nmji_449_2023","relation":{},"ISSN":["2583-150X","0970-258X"],"issn-type":[{"value":"2583-150X","type":"electronic"},{"value":"0970-258X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"article-number":"6"}}